# Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

> **NCT03326310** · PHASE1 · RECRUITING · sponsor: **University of Chicago** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Myelofibroses

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT03326310
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-04
- **Primary completion:** 2027-09-04
- **Final completion:** 2027-09-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326310, "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03326310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*